Russian Journal of OncologyRussian Journal of OncologyРоссийский онкологический журнал1028-99842412-9119Eco-Vector5934010.17816/1028-9984-2020-25-4-146-153Clinical investigationsКлинические исследованияResearch ArticleTargeted therapy in the treatment of HER-2 positive breast cancer with brain metastasesТаргетные препараты в терапии HER2-позитивного рака молочной железы с метастазами в головном мозгеhttps://orcid.org/0000-0002-4218-9652NaskhletashviliDavid R.НасхлеташвилиДавид Романович
Russian Federation

MD, PhD, senior researcher, N.N. Blokhin National Medical Research Center of Oncology

к.м.н., старший научный сотрудник ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Министерства здравоохранения Российской Федерации

nas-david@yandex.ruhttps://orcid.org/0000-0002-6792-967XRoshchinaK. E.РощинаК. Е.
Russian Federation
nas-david@yandex.ruGorbunovaV. A.ГорбуноваВ. А.
Russian Federation
nas-david@yandex.ruhttps://orcid.org/0000-0003-0194-7645GasparyanT. G.ГаспарянТ. Г.
Russian Federation
nas-david@yandex.ruBychkovM. B.БычковМ. Б.
Russian Federation
nas-david@yandex.ruhttps://orcid.org/0000-0002-4160-9598BekyashevA. H.БекяшевА. Х.
Russian Federation
nas-david@yandex.ruhttps://orcid.org/0000-0001-6325-716XKarakhanV. B.КараханВ. Б.
Russian Federation
nas-david@yandex.ruMoskvinaE. A.МосквинаЕ. А.
Russian Federation
nas-david@yandex.ruhttps://orcid.org/0000-0003-1850-5595AleshinV. A.АлешинВ. А.
Russian Federation
nas-david@yandex.ruhttps://orcid.org/0000-0003-1766-0032BelovD. M.БеловД. М.
Russian Federation
nas-david@yandex.ruhttps://orcid.org/0000-0002-4125-7342MitrofanovA. A.МитрофановА. А.
Russian Federation
nas-david@yandex.ruhttps://orcid.org/0000-0001-8880-1758ProzorenkoE. V.ПрозоренкоЕ. В.
Russian Federation
nas-david@yandex.ruPogosovaA. A.ПогосоваА. А.
Russian Federation
nas-david@yandex.ruNational Medical Research Center of Oncology by N.N. Blokhin of the Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Министерства здравоохранения Российской Федерации150820202541461532601202126012021Copyright ©; 2020, Eco-VectorCopyright ©; 2020, ООО "Эко-Вектор"2020Eco-VectorООО "Эко-Вектор"https://rjonco.com/1028-9984/article/view/59340

Metastatic damage to the brain is a frequent manifestation in tumors of various localizations, including breast cancer. Until recently, systemic therapy of metastatic brain damage was of limited use; however, with the advent of targeted drugs that are better understood in terms of the specific molecular targets and biological characteristics of metastases, it is now possible to improve treatment results. In an analysis of the results of studies on the problem of metastasis of breast cancer in the brain, a comparison of the use of various targeted drugs in the treatment of metastatic HER2 + breast cancer is presented. The results of a comparison of the degrees of effectiveness of targeted drugs, both in monotherapy and in combination with chemotherapy, were obtained and analyzed.

Метастатическое поражение головного мозга – частое проявление при опухолях различной локализации, в том числе и при раке молочной железы (РМЖ). До недавнего времени системная терапия метастатического поражения головного мозга имела ограниченное применение, но появление таргетных препаратов позволило не только лучше понять специфические молекулярные мишени и биологические особенности метастазов, но и дало возможность улучшить результаты лечения. В анализе результатов исследований, посвящëнных проблеме метастазирования рака молочной железы в головной мозг, представлено сравнение терапии различными таргетными препаратами при лечении метастатического HER2+ РМЖ. Получены и проанализированы результаты сравнения эффективности таргетных препаратов как в монотерапии, так и в сочетании с химиотерапией.

brainmetastasesbreast cancerHER2 inhibitorsголовной мозгметастазырак молочной железыингибиторы HER2Chissov VI, Starinskiy VV, Petrova GV. Malignant neoplasms in Russia in 2010. Moscow: FGBU “MNIOI im. P.A. Gertsena”; 2012. (In Russ).Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2010 году. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздравсоцразвития России, 2012. С. 1-260.Kennecke H, Yerushalmi R, Woods R, Chon U, Cheang M,Voduc D, et al. Metastatic Behavior of Breast Cancer Subtypes. J Clin Oncol. 2010;28(20):3271–3277. DOI: 10.1200/JCO.2009.25.9820.Kennecke H., Yerushalmi R., Woods R., Chon U Cheang M., Voduc D., et al. Metastatic Behavior of Breast Cancer Subtypes // J Clin Oncol. 2010. Vol. 28. N20. P. 3271–3277. DOI: 10.1200/JCO.2009.25.9820.Semiglazov VF, Paltuev RM, Semiglazov VV, et al. Early breast cancer: the prognostic value of biological subtypes. Analiz nakopitel’noy bazy dannykh FGBU «NII onkologii im. N.N. Petrova» Minzdravsotsrazvitiya. 2012;1–112. DOI: 10.18027/2224-5057-2012-2-12-18. (In Russ).Семиглазов В.Ф., Палтуев Р.М, Семиглазов В.В. c соавт. Ранний рак молочной железы: прогностическое значение биологических подтипов // Анализ кумулятивной базы данных ФГБУ «НИИ Онкологии им. Н.Н. Петрова» Минздравсоцразвития, 2012. С. 1–112. DOI: 10.18027/2224-5057-2012-2-12-18.Bit-Sava EM, Belogurova MB. Hereditary breast cancer. Sibirskiy onkologicheskiy zhurnal. 2013;55(1):1–16. (In Russ).Бит-Сава E.M., Белогурова М.Б. Наследственный рак молочной железы // Сибирский онкологический журнал. 2013. Т. 55. №1. С. 1–16.Plotnikova VE, Nepomnyashchaya EM, Grigorov SV. Risk factors for metastatic brain lesions in breast cancer. Nauchnye vedomosti BelGU. Meditsina. Farmatsiya. 2013;154(11):1–154.(In Russ).Плотникова В.Е., Непомнящая Е.М., Григоров С.В. Факторы риска метастатического поражения головного мозга при раке молочной железы // Научные ведомости БелГУ. Медицина. Фармация. 2013. Т. 154. №11. С. 1–154.Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17). DOI:10.1200/JCO.2004.01.175Lin N.U., Bellon J.R., Winer E.P. CNS metastases in breast cancer // J. Clin Oncol. 2004. Vol. 22. N 17. P. 3608–3617. DOI: 10.1200/JCO.2004.01.175.Demircioglu F, Demirci U, Akmansu M. Lymphnode ratio assessment of brain metastasis in early breast cancer cases. Asian Pacific J Cancer Prev. 2013;14(3):1665–1667. DOI:10.7314/APJCP.2013.14.3.1665.Demircioglu F., Demirci U., Akmansu M. Lymph node ratio assessment of brain metastasis in early breast cancer cases // Asian Pacific J Cancer Prev. 2013. Vol. 14. N 3. P. 1665–1667. DOI: 10.7314/APJCP.2013.14.3.1665.Balkonov AS, Petrushkina NN. Features of metastasis to the brain in patients with luminal subtype of breast cancer. Al’manakh klinicheskoy meditsiny. 2016;44(5):635–639. DOI: 10.18786/2072-0505-2016-44-5-635-639. (In Russ.)Балконов А.С., Петрушкина Н.Н. Особенности метастазирования в головной мозг у пациенток с люминальным подтипом рака молочной железы // Альманах клинической медицины. 2016. Т. 44. №5. С. 635–639. DOI: 10.18786/2072-0505-2016-44-5-635-639.Gabos Z, SinhaR, Hanson J, Chauhan N, Hugh J, Mackey Bassam A.R.J. Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer. Journal of Clinical Oncology. 2006;24(36):5658–5663. DOI: 10200/JCO.2006.07.0250.Gabos Z., Sinha R., HansonJ., Chauhan N., Hugh J., Mackey Bassam A.R.J. Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer // Journal of Clinical Oncology. 2006. Vol. 24. N 36. P. 5658-–5663. DOI: 10.1200/JCO.2006.07.0250.Adam M, Brufsky, et al. Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from regist HER. Clin Cancer Res. 2011;17(14):4834–4843. DOI: 10.1158/1078-0432.CCR-10-2962.Adam M., Brufsky, et al. Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from regist HER //Clin Cancer Res. 2011. Vol. 17. N 14. P. 4834–4843. DOI: 10.1158/1078-0432.CCR-10-2962.Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for central nervous system metastases in trials of the International Breast Cancer Study Group (IBCSG). Annals of Oncology. 2006;17:935–944. DOI: 10.1093/annonc/mdl064.Pestalozzi B.C., Zahrieh D., Price K.N., et al. Identifying breast cancer patients at risk for central nervous system metastases in trials of the International Breast Cancer Study Group (IBCSG) // Annals of Oncology. 2006. Vol. 17. P. 935–944. DOI: 10.1093/annonc/mdl064.Cortés J, Rugo HS, Awada A, Twelves C. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat. 2017;165:329–341. DOI: 10.1007/s10549-017-4304-7.Cortés J., Rugo H.S., Awada A., Twelves C. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial // Breast Cancer Res Treat. 2017. Vol. 165. Р. 329–341. DOI: 10.1007/s10549-017-4304-7.Jahanzeb M, Mortimer JE, Yunus F, Irwin DH, Speyer J, Koletsky AJ, Klein P, Sabir T, Kronish L. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist. 2002;7(5):410–417. DOI: 10.1634/theoncologist.7-5-410.Jahanzeb M., Mortimer J.E., Yunus F., Irwin D.H., Speyer J., Koletsky A.J., Klein P., Sabir T., Kronish L. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer // Oncologist. 2002. Vol. 7. N 5. P. 410–417 DOI: 10.1634/theoncologist.7-5-410.Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Cancer. 2004;91(4):639–643. DOI: 10.1038/sj.bjc.6601970.Clayton A.J., Danson S., Jolly S., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer // Br J Cancer. 2004. Vol. 91. N 4. P. 639–643. DOI: 10.1038/sj.bjc.6601970.Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97(12):2972–2977. DOI:10.1002/cncr.11436.Bendell J.C., Domchek S.M., Burstein H.J., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma // Cancer. 2003. Vol. 97. N 12. P. 2972–2977. DOI: 10.1002/cncr.11436.Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab as first-line chemotherapy for patients with HER2-enhanced metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. Journal of clinical oncology. 2011;29(2):149–156. DOI: 10.1200/jco.2010.28.6450.Valero V., Forbes J., Pegram M.D., et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab as first-line chemotherapy for patients with HER2-enhanced metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens // Journal of clinical oncology. 2011. Vol. 29. N 2. Р. 149–156. DOI: 10.1200/jco.2010.28.6450Harbeck N, Heinemann V, Loibl S, Untchd M. Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer. Breast Care (Basel). 2008;(3 Suppl 1):7–12. DOI: 10.1159/000119744.Harbeck N., Heinemann V., Loibl S., Untchd M. Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer // Breast Care (Basel). 2008. N 3. Suppl. 1. P. 7–12. DOI: 10.1159/000119744.Bachelot T, Romieu G, Campone M, Diéras V, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71. DOI: 10.1016/S1470Bachelot T., Romieu G., Campone M., Diéras V., et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study // Lancet Oncol. 2013. Vol. 14. N 1. P. 64–71. DOI: 10.1016/S1470-2045(12)70432-1.Naskhletashvili DR, Gorbunova VA, Moskvina EA. Chemotherapy and targeted therapy of breast cancer patients with metastatic brain lesions. Opukholi golovy i shei. 2014;(4):17–21. (In Russ).Насхлеташвили Д.Р., Горбунова В.А., Москвина Е.А. Химио- и таргетная терапия больных раком молочной железы с метастатическим поражением головного мозга // Опухоли головы и шеи. 2014. № 4. С. 17–21.Amiri-Kordestani L, Blumenthal GM, Xu QC, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER-2-positive metastatic breast cancer. Clin. Cancer Res. 2014;20(17):4436–4441. DOI: 10.1158/1078-0432.CCR-14-0012.Amiri-Kordestani L., Blumenthal G.M., Xu Q.C., et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER-2-positive metastatic breast cancer // Clin Cancer Res. 2014. Vol. 20. N 17. P. 4436–4441. DOI: 10.1158/1078-0432.CCR-14-0012.Krop IE, Lin NU, Blackwell K, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113–119. DOI: 10.1093/annonc/mdu486.Krop I.E., Lin N.U., Blackwell K., et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA //Ann Oncol. 2015. Vol. 26. N 1. P. 113–119. DOI: 10.1093/annonc/mdu486.Vici P, Pizzuti L, Michelotti A, et al. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget. 2017;8(34):56921–56931. DOI: 10.18632/oncotarget.18176.Vici P., Pizzuti L., Michelotti A., et al. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience // Oncotarget. 2017. Vol. 8. N 34. P. 56921–56931. DOI: 10.18632/oncotarget.18176.Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–377. DOI: 10.1016/S1470-2045(15)00551-3Chan A., Delaloge S., Holmes F.A., et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial // Lancet Oncol. 2016. Vol.17. N 3. P. 367–377. DOI: 10.1016/S1470-2045(15)00551-3.Awada A, Colomer R, Inoue K, et al. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. JAMA Oncol. 2016;2(12):1557–1564. DOI: 10.1001/jamaoncol.2016.0237.Awada A., Colomer R., Inoue K., et al. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial // JAMA Oncol. 2016. Vol. 2. N 12. P. 1557–1564. DOI: 10.1001/jamaoncol.2016.0237.Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, et al. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. Clin. Oncol. 2016;34(9):945–952. DOI: 10.1200/JCO.2015.63.0343.Freedman R.A., Gelman R.S., Wefel J.S., Melisko M.E., Hess K.R.,Connolly R.M., et al. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases // J Clin Oncol. 2016. Vol. 34.N 9. P. 945–952. DOI: 10.1200/JCO.2015.63.0343.Saura C, Garcia-Saenz JA, Xu B, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. Clin Oncol. 2014;32(32):3626–3633. DOI: 10.1200/JCO.2014.56.3809.Saura C., Garcia-Saenz J.A., Xu B., et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer // Journal of Clinical Oncology. 2014. Vol. 32. N 32.P. 3626-3633. DOI: 10.1200/JCO.2014.56.3809.